PMC:7276833 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"1","span":{"begin":14,"end":35},"obj":"Disease"},{"id":"11","span":{"begin":115,"end":125},"obj":"Species"},{"id":"12","span":{"begin":267,"end":275},"obj":"Species"},{"id":"13","span":{"begin":599,"end":607},"obj":"Species"},{"id":"14","span":{"begin":84,"end":92},"obj":"Disease"},{"id":"15","span":{"begin":281,"end":294},"obj":"Disease"},{"id":"16","span":{"begin":306,"end":314},"obj":"Disease"},{"id":"17","span":{"begin":424,"end":436},"obj":"Disease"},{"id":"18","span":{"begin":495,"end":509},"obj":"Disease"},{"id":"19","span":{"begin":650,"end":671},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"tao:has_database_id","subj":"1","obj":"MESH:D006528"},{"id":"A11","pred":"tao:has_database_id","subj":"11","obj":"Tax:2697049"},{"id":"A12","pred":"tao:has_database_id","subj":"12","obj":"Tax:9606"},{"id":"A13","pred":"tao:has_database_id","subj":"13","obj":"Tax:9606"},{"id":"A14","pred":"tao:has_database_id","subj":"14","obj":"MESH:C000657245"},{"id":"A15","pred":"tao:has_database_id","subj":"15","obj":"MESH:D008107"},{"id":"A16","pred":"tao:has_database_id","subj":"16","obj":"MESH:C000657245"},{"id":"A17","pred":"tao:has_database_id","subj":"17","obj":"MESH:D006528"},{"id":"A18","pred":"tao:has_database_id","subj":"18","obj":"MESH:D008107"},{"id":"A19","pred":"tao:has_database_id","subj":"19","obj":"MESH:D058625"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Management of Hepatocellular Cancer in the time of SARS‐CoV‐2\n\nAbstract\nAbstract\nAs COVID‐19 the disease caused by SARS‐CoV‐2 continues to have a profound impact on global health, there have been a number of guidelines recently published addressing the management of patients with liver disease during the COVID‐19 pandemic including the recently published EASL‐ESCMID Position Paper, guidelines issued by the International Liver Cancer Association and the American Association for the Study of Liver Diseases (1‐3). All publications present a sound discussion regarding the challenges face by both patients and clinicians alike in the management of chronic liver disease in the setting of this ongoing pandemic.\n\n"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T1","span":{"begin":281,"end":286},"obj":"Body_part"},{"id":"T2","span":{"begin":424,"end":429},"obj":"Body_part"},{"id":"T3","span":{"begin":495,"end":500},"obj":"Body_part"},{"id":"T4","span":{"begin":586,"end":590},"obj":"Body_part"},{"id":"T5","span":{"begin":658,"end":663},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"fma_id","subj":"T1","obj":"http://purl.org/sig/ont/fma/fma7197"},{"id":"A2","pred":"fma_id","subj":"T2","obj":"http://purl.org/sig/ont/fma/fma7197"},{"id":"A3","pred":"fma_id","subj":"T3","obj":"http://purl.org/sig/ont/fma/fma7197"},{"id":"A4","pred":"fma_id","subj":"T4","obj":"http://purl.org/sig/ont/fma/fma24728"},{"id":"A5","pred":"fma_id","subj":"T5","obj":"http://purl.org/sig/ont/fma/fma7197"}],"text":"Management of Hepatocellular Cancer in the time of SARS‐CoV‐2\n\nAbstract\nAbstract\nAs COVID‐19 the disease caused by SARS‐CoV‐2 continues to have a profound impact on global health, there have been a number of guidelines recently published addressing the management of patients with liver disease during the COVID‐19 pandemic including the recently published EASL‐ESCMID Position Paper, guidelines issued by the International Liver Cancer Association and the American Association for the Study of Liver Diseases (1‐3). All publications present a sound discussion regarding the challenges face by both patients and clinicians alike in the management of chronic liver disease in the setting of this ongoing pandemic.\n\n"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T1","span":{"begin":281,"end":286},"obj":"Body_part"},{"id":"T2","span":{"begin":424,"end":429},"obj":"Body_part"},{"id":"T3","span":{"begin":495,"end":500},"obj":"Body_part"},{"id":"T4","span":{"begin":586,"end":590},"obj":"Body_part"},{"id":"T5","span":{"begin":658,"end":663},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"A2","pred":"uberon_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"A3","pred":"uberon_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"A4","pred":"uberon_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/UBERON_0001456"},{"id":"A5","pred":"uberon_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/UBERON_0002107"}],"text":"Management of Hepatocellular Cancer in the time of SARS‐CoV‐2\n\nAbstract\nAbstract\nAs COVID‐19 the disease caused by SARS‐CoV‐2 continues to have a profound impact on global health, there have been a number of guidelines recently published addressing the management of patients with liver disease during the COVID‐19 pandemic including the recently published EASL‐ESCMID Position Paper, guidelines issued by the International Liver Cancer Association and the American Association for the Study of Liver Diseases (1‐3). All publications present a sound discussion regarding the challenges face by both patients and clinicians alike in the management of chronic liver disease in the setting of this ongoing pandemic.\n\n"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T1","span":{"begin":14,"end":35},"obj":"Disease"},{"id":"T4","span":{"begin":51,"end":55},"obj":"Disease"},{"id":"T5","span":{"begin":84,"end":92},"obj":"Disease"},{"id":"T6","span":{"begin":115,"end":119},"obj":"Disease"},{"id":"T7","span":{"begin":281,"end":294},"obj":"Disease"},{"id":"T8","span":{"begin":306,"end":314},"obj":"Disease"},{"id":"T9","span":{"begin":424,"end":436},"obj":"Disease"},{"id":"T12","span":{"begin":430,"end":436},"obj":"Disease"},{"id":"T13","span":{"begin":658,"end":671},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0007256"},{"id":"A2","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0016216"},{"id":"A3","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0018055"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A5","pred":"mondo_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A6","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A7","pred":"mondo_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MONDO_0005154"},{"id":"A8","pred":"mondo_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A9","pred":"mondo_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/MONDO_0002691"},{"id":"A10","pred":"mondo_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/MONDO_0007256"},{"id":"A11","pred":"mondo_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/MONDO_0018531"},{"id":"A12","pred":"mondo_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"},{"id":"A13","pred":"mondo_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/MONDO_0005154"}],"text":"Management of Hepatocellular Cancer in the time of SARS‐CoV‐2\n\nAbstract\nAbstract\nAs COVID‐19 the disease caused by SARS‐CoV‐2 continues to have a profound impact on global health, there have been a number of guidelines recently published addressing the management of patients with liver disease during the COVID‐19 pandemic including the recently published EASL‐ESCMID Position Paper, guidelines issued by the International Liver Cancer Association and the American Association for the Study of Liver Diseases (1‐3). All publications present a sound discussion regarding the challenges face by both patients and clinicians alike in the management of chronic liver disease in the setting of this ongoing pandemic.\n\n"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T1","span":{"begin":144,"end":145},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T2","span":{"begin":196,"end":197},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T3","span":{"begin":281,"end":286},"obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"T4","span":{"begin":281,"end":286},"obj":"http://www.ebi.ac.uk/efo/EFO_0000887"},{"id":"T5","span":{"begin":424,"end":429},"obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"T6","span":{"begin":424,"end":429},"obj":"http://www.ebi.ac.uk/efo/EFO_0000887"},{"id":"T7","span":{"begin":495,"end":500},"obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"T8","span":{"begin":495,"end":500},"obj":"http://www.ebi.ac.uk/efo/EFO_0000887"},{"id":"T9","span":{"begin":542,"end":543},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T10","span":{"begin":586,"end":590},"obj":"http://purl.obolibrary.org/obo/UBERON_0001456"},{"id":"T11","span":{"begin":658,"end":663},"obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"T12","span":{"begin":658,"end":663},"obj":"http://www.ebi.ac.uk/efo/EFO_0000887"}],"text":"Management of Hepatocellular Cancer in the time of SARS‐CoV‐2\n\nAbstract\nAbstract\nAs COVID‐19 the disease caused by SARS‐CoV‐2 continues to have a profound impact on global health, there have been a number of guidelines recently published addressing the management of patients with liver disease during the COVID‐19 pandemic including the recently published EASL‐ESCMID Position Paper, guidelines issued by the International Liver Cancer Association and the American Association for the Study of Liver Diseases (1‐3). All publications present a sound discussion regarding the challenges face by both patients and clinicians alike in the management of chronic liver disease in the setting of this ongoing pandemic.\n\n"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T1","span":{"begin":29,"end":35},"obj":"Phenotype"},{"id":"T2","span":{"begin":281,"end":294},"obj":"Phenotype"},{"id":"T3","span":{"begin":424,"end":436},"obj":"Phenotype"},{"id":"T4","span":{"begin":495,"end":509},"obj":"Phenotype"},{"id":"T5","span":{"begin":658,"end":671},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/HP_0002664"},{"id":"A2","pred":"hp_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/HP_0001392"},{"id":"A3","pred":"hp_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/HP_0002896"},{"id":"A4","pred":"hp_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/HP_0001392"},{"id":"A5","pred":"hp_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/HP_0001392"}],"text":"Management of Hepatocellular Cancer in the time of SARS‐CoV‐2\n\nAbstract\nAbstract\nAs COVID‐19 the disease caused by SARS‐CoV‐2 continues to have a profound impact on global health, there have been a number of guidelines recently published addressing the management of patients with liver disease during the COVID‐19 pandemic including the recently published EASL‐ESCMID Position Paper, guidelines issued by the International Liver Cancer Association and the American Association for the Study of Liver Diseases (1‐3). All publications present a sound discussion regarding the challenges face by both patients and clinicians alike in the management of chronic liver disease in the setting of this ongoing pandemic.\n\n"}

{"project":"LitCovid-sentences","denotations":[{"id":"T1","span":{"begin":0,"end":61},"obj":"Sentence"},{"id":"T2","span":{"begin":63,"end":71},"obj":"Sentence"},{"id":"T3","span":{"begin":72,"end":80},"obj":"Sentence"},{"id":"T4","span":{"begin":81,"end":516},"obj":"Sentence"},{"id":"T5","span":{"begin":517,"end":712},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Management of Hepatocellular Cancer in the time of SARS‐CoV‐2\n\nAbstract\nAbstract\nAs COVID‐19 the disease caused by SARS‐CoV‐2 continues to have a profound impact on global health, there have been a number of guidelines recently published addressing the management of patients with liver disease during the COVID‐19 pandemic including the recently published EASL‐ESCMID Position Paper, guidelines issued by the International Liver Cancer Association and the American Association for the Study of Liver Diseases (1‐3). All publications present a sound discussion regarding the challenges face by both patients and clinicians alike in the management of chronic liver disease in the setting of this ongoing pandemic.\n\n"}